A ortic valve disease in the United States is a major cardiovascular problem that is likely to grow as the population ages. [1] [2] [3] [4] [5] Aortic valve replacement is the standard treatment even for very elderly patients despite its risks in this age group. 6 With transcatheter aortic valve replacement emerging as a less invasive option, [7] [8] [9] contemporary data from real-world practice are needed to provide a perspective on the outcomes that are being achieved with surgery. Changes in practice during the past decade are partly due to growing recognition that the benefits of aortic valve replacement extend to extremes in patient age. 10, 11 There is also a recommendation for consideration of earlier, preemptive aortic valve replacement in selected asymptomatic patients 12 and strong guidance that bioprostheses rather than mechanical valves be used for patients 65 years or older. 13, 14 There is also uncertainty about the benefit of performing coronary artery bypass graft (CABG) surgery during aortic valve replacement in patients with stable coronary disease. 8, 15, 16 Previous studies have indicated that rates of aortic valve replacement are increasing and outcomes are improving [17] [18] [19] [20] but do not provide population-based rates and long-term follow-up. [17] [18] [19] [20] We therefore studied aortic valve replacement among Medicare fee-for-service beneficiaries between 1999 and 2011. We calculated trends in rates of surgical aortic valve replacement and outcomes defined as mortality, readmission, and length of stay. In addition, we compared the outcomes of pa-terns of care and outcomes across subgroups may indicate opportunities for quality improvement, we also calculated these trends by age, sex, and race.
Methods

Study Sample
Institutional review board approval for this study was obtained through the Yale University Human Investigation Committee. We identified all Medicare fee-for-service patients from January 1, 1999, to December 31, 2011, using the inpatient administrative data from the Centers for Medicare & Medicaid Services (CMS). We identified patients who underwent aortic valve replacement based on the principal discharge diagnosis (International Classification of Diseases, Ninth Revision, Clinical Modification codes 35.21 [aortic valve surgery replacement with bioprosthesis], and 35.22 [aortic valve surgery replacement with mechanical prosthesis]; eTable 1 in the Supplement). We excluded 566 patients who underwent aortic valve repair, 37 412 who underwent aortic valve replacement with concomitant mitral valve surgery, and 4007 who underwent tricuspid valve surgery from the years 1999 to 2011, and 2961 who had endocarditis as their principal diagnosis. For a small group of patients who had more than 1 aortic valve replacement during any of the study years-a proportion that decreased over time (n=389, or 1.5% in 1999 and 44 or 0.1% in 2011)-we selected the first procedure. We linked aortic valve replacement data with Medicare denominator files to obtain mortality information and to determine the eligibility of the beneficiaries and their length of time in the fee-for-service program.
Patient Characteristics
We collected data on patients' age, sex, race, and common comorbidities. Race was determined from the Medicare denominator files, which used patient-reported data from the Social Security Administration. 23 We selected 21 comorbidities in categories of cardiovascular disease (hypertension, diabetes mellitus, atherosclerotic disease, unstable angina, prior myocardial infarction, prior heart failure, peripheral vascular disease, stroke, non-stroke cerebrovascular disease), geriatric conditions (dementia, functional disability, malnutrition), and miscellaneous (renal failure, chronic obstructive pulmonary disease, pneumonia, respiratory failure, liver disease, cancer, major psychiatric disorders, depression, and trauma) based on the method used by CMS for profiling hospitals for acute myocardial infarction and heart failure. 24, 25 We identified comorbidities from diagnosis codes of all patient hospitalizations for any cause, primary or secondary, up to 1 year before the initial hospitalization for aortic valve replacement. Comorbidity data from 1998 were used for patients who underwent an aortic valve replacement in 1999. 
Statistical Analysis
We express the rate of aortic valve replacement per 100 000 person-years, the rates of mortality and readmission as percentages, and length of stay as median (interquartile range) days. We used the Mantel-Haenszel χ 2 test to determine the statistical significance of temporal changes in observed outcomes and patient characteristics. To evaluate changes in rates of aortic valve replacement, we fit a mixed-effects model with a Poisson link function and state-specific random intercepts, adjusting for age, sex, and race. To estimate changes in the rates of mortality (30-day and 1-year), we used the same mixed model with a logit-link function and hospital-specific random intercepts, adjusting for patient age, sex, race, and comorbidities.
To assess change in rates of 30-day readmission, we constructed a Cox proportional hazards model with death as a censoring event and adjusting for age, sex, race and comorbidity. We used the method developed by Lin et al 28 to check the adequacy of the Cox regression model and found the proportional hazards assumption was satisfied. All models included an ordinal time variable ranged from 0 to 12, corresponding to the years 1999 to 2011, to represent the annual changes in outcomes. The incidence rate ratio (RR) of the time variable was used to represent the age-, sex-, and race-adjusted annual changes in the aortic valve replacement rate, and the odds ratio (OR) and hazard ratio (HR) of the time variable were used to represent the age-, sex-, and race-
Results
Patient Characteristics and Comorbidities
The final sample consisted of 409 591 889 records, representing 82 755 924 beneficiaries aged 65 years or older with at least 1 month of enrollment in Medicare fee-for-service during the study period (2 542 827 477 person-years). Patient age, sex, and race remained mostly unchanged over time but several comorbidities were more commonly coded, including hypertension (51.8% in 1999, 65.7% in 2011), diabetes mellitus (21.0% in 1999, 27.7% in 2011), and renal failure (2.4% in 1999, 10.4% in 2011). Atherosclerotic disease (60.7% in 1999, 57.2% in 2011) and history of heart failure (18.4% in 1999, 17.6% in 2011) were reported less frequently (P <.001 for trend) ( Table 1 and eTable 2, in the Supplement). 
Rates of Aortic Valve Replacement
Rates of Mortality
Between 1999 and 2011, 30-day mortality rates decreased an absolute 3.4% (95% CI, 3.0%-3.8%) for all aortic valve replacement, an absolute 3.1% (95% CI, 2.6%-3.7%) for aortic valve replacement without CABG surgery, and an absolute 3.2% (95% CI, 2.6%-3.8%) for aortic valve replacement with CABG surgery. One-year mortality rates also decreased by an absolute 2.6% (95% CI, 2.1%-3.2%) for all aortic valve replacements, 2.2% (95% CI 1.5% to 3.0%) for aortic valve replacement without CABG surgery, and 2.4% (95% CI 1.6% to 3.2%) for aortic valve replacement with CABG surgery. The decreases were similar among all age, sex, and race strata (Table 3 and eTable 5, in the Supplement) and did not change substantially after accounting for patient characteristics and hospital. Age-, sex-, and racecomorbidity-adjusted decreases in 30-day mortality rates were 4.1% (95% CI, 3.7%-4.4%) per year (OR, 0.959; 95% CI, 0.956-0.963) for overall aortic valve replacement, 4.7% (95% CI, 4.2%-5.3%) per year (OR, 0.953, 95% CI, 0.947-0.958) for aortic valve replacement without CABG, and 3.4% (95% CI, 2.9%-3.8%) per year (OR, 0.966; 95% CI, 0.962-0.971) for aortic valve replacement with CABG surgery. Similarly, the age-, sex-, and racecomorbidity-adjusted decreases in 1-year mortality rates were 2.5% (95% CI, 2.3%-2.8%) per year (OR, 0.975; 95% CI, 0.972-0.977) for all aortic valve replacement, 2.8% (95% CI, 2.3%-3.2%) per year (OR 0.972, 95% CI, 0.968-0.977) for aortic valve replacement without CABG surgery, and 2.1% (95% CI, 1.7%-2.5%) per year (OR, 0.979; 95% CI, 0.975-0.983) for aortic valve replacement with CABG surgery. The decreases were seen among all age, sex, and race strata with the exception of a nonstatistically significant estimate of no change in 1-year mortality among nonwhite nonblack women undergoing aortic valve surgery with CABG surgery (eFigure, eTables 6 and 7 in the Supplement). Although decreases in mortality were comparable within sex and race strata, women nevertheless had higher 30-day and 1-year mortality than men, and black patients had higher mortality than white patients in every study year.
Length of Stay and Rates of Readmission
Median length of stay was unchanged (Table 3 and eTable 5, in the Supplement). Thirty-day readmission rates decreased slightly for aortic valve replacement procedures overall and with and without CABG surgery (Table 3) . Age-, sex-, and race- Abbreviations: AVR, aortic valve replacement; CABG, coronary artery bypass graft surgery; IQR, interquartile range.
Research Original Investigation
Trends in Aortic Valve Replacement for Elderly Patients
Type of Valve Surgery
Use of bioprostheses in aortic valve replacement increased from 44.1% in 1999 to 72.7% in 2011 (P < .001). Conversely, mechanical prosethetic implants decreased from 55.9% to 27.3% (P<.001). Among age, sex, and race strata in 2011, use of bioprostheses was highest for patients who were 85 years or older, men, and white (eTable 9 in the Supplement). In 1999, 46.2% of patients 85 years or older received a mechanical prosthesis, decreasing to 23.9% in 2011.
Discussion
Our study describes a national increase in the rates of aortic valve replacement and a reduction in mortality, readmission, and length of stay for Medicare beneficiaries undergoing the procedure from 1999 through 2011. Rates of aortic valve replacement without CABG surgery increased while rates of aortic valve replacement with it decreased, but adjusted annual decreases in 30-day mortality were comparable for either procedure. Mechanical aortic valve prostheses continued to be used in about a quarter of elderly patients in 2011. Several studies have investigated this topic with less contemporary cohorts, but direct comparison between our results and those of other studies is difficult because other studies looked at smaller cohorts and few provided a comprehensive national perspective or reported standardized short-and long-term outcomes. focused on aortic valve replacement without CABG surgery in the Society of Thoracic Surgeons database and reported higher survival rates, with age-, sex-, and race-comorbidityadjusted operative mortality decreasing from 3.5% to 2.4% between 1997 and 2006. Our data set extended to 2011, and we found higher mortality for patients undergoing aortic valve replacement without CABG surgery (6.6% in 1999 and 3.5% in 2011), which we believe is likely due to the older age of our population and our use of 30-day (rather than inhospital) mortality as an outcome measure. In addition to providing more contemporary estimates, our study provides longer-term (1-year) mortality outcomes, data on readmission, and outcomes from centers that may not have been captured in Society of Thoracic Surgeons data. Across all years of observation, we found lower procedure rates and higher mortality in black patients than in white patients. Racial differences in aortic valve disease or black patients being referred at a later stage of illness and having less access to the procedure may be factors. [32] [33] [34] [35] [36] Similarly for women, procedure rates were lower and mortality was higher.
A report from the Society of Thoracic Surgeons database of patients undergoing aortic valve replacement without CABG surgery described a similar finding: fewer patients undergoing the procedure were women (43% women vs 57% men) and mortality was higher among women (2006 mortality: 3.2% in women, 2.1% in men). 19 We could not determine reasons for any differences from the Medicare data set, but they point to a worthwhile direction for future investigation. Encouragingly, mortality rates declined among all subgroups from 1999 to 2011, although residual differences persisted. There are several potential explanations for the increase in the use of aortic valve replacement among older adults, including better access to specialized health care centers and enhanced awareness of the therapeutic benefit of aortic valve replacement independent of patient age among health care professionals. 11 The increase in age and comorbidities among patients undergoing aortic valve replacement suggest that the recommendation to perform preemptive aortic valve surgery earlier in the disease course had not taken hold during the study period. Although the largest increase in rates of aortic valve replacement occurred in those aged 85 years or older, a group in which the rate of 1-year mortality was 17.5% by 2011, these patients still underwent surgery less commonly than those aged 75 through 84 years, despite the known increasing prevalence of aortic stenosis with advancing age. 1 This finding suggests that there is a significant residual population of very elderly patients with aortic stenosis for whom transcatheter aortic valve replacement may emerge as a common treatment modality. In that context, our findings could provide a useful benchmark of outcomes with surgical aortic valve replacement among eligible patients who may also be considering transcatheter aortic valve replacement. Approximately 50% of aortic valve replacement procedures were performed with CABG surgery, and we could not determine from our data whether the decrease in aortic valve replacement with CABG surgery over time reflected changing coronary anatomy among the study population (eg, lower prevalence of lesions amenable to surgical revascularization), an increasing use of preprocedural or postprocedural percutaneous coronary intervention, or some other factor. The treatment of chronic coronary artery disease in the setting of aortic valve replacement is uncertain and evolving. 15 CABG surgery continues to be performed during aortic valve replacement in cases of anatomical coronary obstruction. Future studies are needed to investigate whether the current practice of aortic valve replacement plus CABG surgery for patients with stable coronary artery disease is preferable to other strategies such as aortic valve replacement plus watchful waiting, aortic valve replacement plus percutaneous coronary intervention (hybrid procedure), or transcatheter aortic valve replacement plus percutaneous coronary intervention.
administrative data, however, lacked detailed information that could explain the high rate of use of mechanical prostheses. Small native aortic valve annulus or preexisting clinical conditions for anticoagulation may represent some appropriate uses of mechanical prostheses in the elderly. The high rates of mechanical prostheses that we observed in 2011 raise concern about whether this practice is in the best interest of patients. This study has several limitations. First, our findings are observational and multiple factors may have accounted for the observed trends (eg, patient selection, health care system changes, secular changes). We cannot determine the underlying causes due to the limitations of administrative data. Second, our mortality adjustment models used comorbidity information based on administrative data and did not include some relevant clinical information that could have improved the modeling process, such as patient functional status, left ventricular function, the pathological process associated with aortic valve dysfunction, previous cardiac surgery, or the distinction between elective or urgent aortic valve replacement. 41 Third, we used Medicare claims data to infer trends in the type of surgery performed (bioprosthetic implant or mechanical prostheses). Because we used codes for the primary diagnosis, aortic valve disease may have been misclassified as the primary diagnosis in cases of aortic dissection or aneurysm with concomitant aortic valve disease. However, this would represent a very small number of patients. Fourth, our cohort was limited to Medicare feefor-service beneficiaries, and thus we cannot comment on trends among patients enrolled in Medicare managed care programs or among patients younger than 65 years. Because more patients have enrolled in Medicare managed care programs over time, 42 the Medicare fee-for-service population may have changed and therefore affected the observed trends. However, we are reporting rates that take into account any change in the denominator over the years. Finally, the use of inpatient claims limited our ability to include comorbidity information in our procedure rate model, so we were therefore unable to estimate the influence of changes in patient comorbidity on patient selection for an aortic valve replacement.
Conclusions
We found an increase in rates of aortic valve replacement and an improvement in mortality and other outcomes among Medicare beneficiaries over a 12-year period. Rates of aortic valve replacement with CABG surgery decreased, older patients are still receiving mechanical prostheses despite recommendations to the contrary, and women and black patients experienced higher mortality than men and white patients. These findings may provide a useful benchmark for outcomes of aortic valve replacement surgery for older patients eligible for surgery considering newer transcatheter treatments.
